Crinetics Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Details

announced positive topline results from its Phase 2 trial of atumelnant, a novel oral ACTH receptor antagonist for the treatment of classic CAH and ACTH-dependent Cushing's syndrome. The study demonstrated statistically significant reductions in key biomarkers, and meaningful improvements in clinical signs and symptoms of CAH. The safety and efficacy data support the initiation of a Phase 3 clinical trial. The results were announced via a press release and a corporate presentation, which are attached as Exhibits 99.1 and 99.2, respectively.

Items reported

Exhibits (2)

About Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.